Acrivon Therapeutics (ACRV) Share-based Compensation (2021 - 2026)
Acrivon Therapeutics (ACRV) posted quarterly Share-based Compensation of $2.2 million for Q1 2026, down 42.47% year-over-year from $3.8 million in Q1 2025, and down 29.44% quarter-over-quarter from $3.1 million in Q4 2025.
Acrivon Therapeutics (ACRV) Share-based Compensation (2021 - 2026) Analysis & Trends
Acrivon Therapeutics (ACRV) has reported Share-based Compensation for 6 consecutive years, with $2.2 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Share-based Compensation fell 42.47% year-over-year to $2.2 million; the TTM figure through Mar 2026 stood at $13.0 million (down 48.57% YoY), while the FY2025 annual figure was $14.7 million, up 3.02% from the prior year.
- Share-based Compensation retreated to $2.2 million in Q1 2026 per ACRV's latest filing, from $3.1 million in the prior quarter.
- Across five years, Share-based Compensation topped out at $14.2 million in Q4 2024 and bottomed at $40000.0 in Q1 2022.
- Historically, Share-based Compensation has averaged $3.8 million across 5 years, with a median of $3.1 million in 2025.
- Annual changes were most pronounced in 2023 — Share-based Compensation jumped 6515.0% — and 2025, when it slumped 78.28%.
- Acrivon Therapeutics' Share-based Compensation stood at $1.6 million in 2022, then jumped by 85.9% to $3.1 million in 2023, then soared by 365.4% to $14.2 million in 2024, then plunged by 78.28% to $3.1 million in 2025, then decreased by 29.44% to $2.2 million in 2026.
- Business Quant data shows ACRV's Share-based Compensation at $2.2 million in Q1 2026, $3.1 million in Q4 2025, and $12.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 120.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 137.41 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 86.63 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 41.25 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 28.05 Mn |
| 10 | Acrivon Therapeutics | 92.26 Mn | 92.26 Mn | - | 2.21 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.21 Mn |
| Jun 30, 2026 | 2.21 Mn |
| Mar 31, 2026 | 2.18 Mn |
| Mar 31, 2026 | 2.18 Mn |
| Dec 31, 2025 | 3.09 Mn |
| Dec 31, 2025 | 3.09 Mn |
| Sep 30, 2025 | 12.70 Mn |
| Sep 30, 2025 | 12.70 Mn |
| Jun 30, 2025 | 3.93 Mn |
| Jun 30, 2025 | 3.93 Mn |
| Mar 31, 2025 | 3.79 Mn |
| Mar 31, 2025 | 3.79 Mn |
| Dec 31, 2024 | 14.23 Mn |
| Dec 31, 2024 | 14.23 Mn |
| Sep 30, 2024 | 3.67 Mn |
| Sep 30, 2024 | 3.67 Mn |
| Jun 30, 2024 | 3.57 Mn |
| Jun 30, 2024 | 3.57 Mn |
| Mar 31, 2024 | 3.34 Mn |
| Mar 31, 2024 | 3.34 Mn |